Regulatory Considerations for the Clinical Translation of Stem Cell‐Derived Extracellular Vesicle Products
Journal of Extracellular Vesicles · 2026-11 · 15 (11)
DOI: 10.1002/jev2.70378 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Extracellular Vesicles, online erschienen am 15.11.2026. Verfasst von Jiaqi Lu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Evaluation, National Medical Products Administration, Beijing, China. Hauptthemen laut MEDLINE: Extracellular Vesicles, Stem Cells, Translational Research, Biomedical. Die Arbeit nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China, State Key Laboratory of Drug Regulatory Science Project.
Abstract (Originalsprache)
Extracellular vesicles (EVs) have emerged as one type of the innovative medicinal products possessing low immunogenicity, cargo‐loading capacity, and potential tissue tropism. The clinical translation of stem cell‐derived EV products is advancing fast, while significant challenges exist, including complex manufacturing processes, heterogeneity in molecular composition, and diversified mechanisms of actions. The inherent variability poses obstacles for the regulatory evaluation and approval of EV products. This review provides Chemistry, Manufacturing, and Control (CMC) evaluation considerations on the stem cell‐derived EV products under drug regulatory paradigms. Specifically, critical aspects essential for Investigational New Drug (IND) applications are discussed, including the establishment of cell substrates, raw materials, manufacturing process development, viral safety, quality characterization, specification setting, stability, and comparability studies. In addition, this review summarizes the development landscape of EV products in China and globally, analyses difficulties in process and quality standardizations, and explores the translational potential and hurdles in EV products development. The aim is to provide an operational framework for EV developers from bench to bedside.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Drug Evaluation, National Medical Products Administration, Beijing, China.
ORCID-Profile: Jiaqi Lu
Förderung
- National Key Research and Development Program of China
- State Key Laboratory of Drug Regulatory Science Project
Zitieren
APA
Lu, J., Gong, X., Wang, J., Dong, J., Wang, X., Han, D., Cui, J., Chen, H., & Wei, W. (2026). Regulatory Considerations for the Clinical Translation of Stem Cell‐Derived Extracellular Vesicle Products. Journal of Extracellular Vesicles, 15(11). https://doi.org/10.1002/jev2.70378
Vancouver
Lu J, Gong X, Wang J, Dong J, Wang X, Han D, et al. Regulatory Considerations for the Clinical Translation of Stem Cell‐Derived Extracellular Vesicle Products. Journal of Extracellular Vesicles. 2026;15(11). doi:10.1002/jev2.70378
BibTeX
@article{Lu2026,
author = {Lu, Jiaqi and Gong, Xu and Wang, Jingyu and Dong, Jing and Wang, Xue and Han, Dongmei and Cui, Jing and Chen, Hao and Wei, Wei},
title = {Regulatory Considerations for the Clinical Translation of Stem Cell‐Derived Extracellular Vesicle Products},
journal = {Journal of Extracellular Vesicles},
year = {2026},
volume = {15},
number = {11},
doi = {10.1002/jev2.70378}
}
EUVIMED